KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Asset Writedowns and Impairment: 2015-2024

Historic Asset Writedowns and Impairment for Travere Therapeutics (TVTX) over the last 7 years, with Dec 2024 value amounting to $2.8 million.

  • Travere Therapeutics' Asset Writedowns and Impairment fell 17.96% to -$1.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.0 million, marking a year-over-year increase of 108.63%. This contributed to the annual value of $2.8 million for FY2024, which is 7.24% down from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' Asset Writedowns and Impairment is $2.8 million, which was down 7.24% from $3.0 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Asset Writedowns and Impairment registered a high of $3.0 million during FY2023, and its lowest value of $498,000 during FY2021.
  • Its 3-year average for Asset Writedowns and Impairment is $2.3 million, with a median of $2.8 million in 2024.
  • Per our database at Business Quant, Travere Therapeutics' Asset Writedowns and Impairment crashed by 91.27% in 2020 and then skyrocketed by 192.49% in 2023.
  • Yearly analysis of 5 years shows Travere Therapeutics' Asset Writedowns and Impairment stood at $2.2 million in 2020, then slumped by 77.62% to $498,000 in 2021, then surged by 108.63% to $1.0 million in 2022, then soared by 192.49% to $3.0 million in 2023, then decreased by 7.24% to $2.8 million in 2024.